CONGRESS ASSET MANAGEMENT CO

Position in HALO — Halozyme Therapeutics, Inc.

CIK 897378 BOSTON, MA

Position in HALO

as of Jun 30, 2026 · filed Jul 7, 2026 Compact

Position Value

$96,202,126

+$13,437,466 QoQ

Shares Held

1,229,106

-4.0% QoQ

Ownership

1.08%

of shares outstanding

% of Portfolio

0.60%

of 13F equity value

Holder Rank

#31

of 664 holders

Holding Since

Jun 2023

13 quarters on record

Voting authority Sole 89% Shared 7% None 4%

Healthcare · as of Jun 30, 2026

CONGRESS ASSET MANAGEMENT CO holds $715,705,658 across 14 Biotechnology names. HALO ranks #4 (13.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	LGND	Ligand Pharmaceuticals Inc	659,911	$208,591,267
2	TGTX	Tg Therapeutics, Inc.	2,600,123	$142,850,757
3	VCEL	Vericel Corp	2,916,295	$129,745,964
4	HALO	Halozyme Therapeutics, Inc. This page	1,229,106	$96,202,126
5	ALNY	Alnylam Pharmaceuticals, Inc.	265,701	$79,983,972
6	KRYS	Krystal Biotech, Inc.	40,134	$14,916,603
7	TNGX	Tango Therapeutics, Inc.	380,746	$11,902,119
8	RLAY	Relay Therapeutics, Inc.	626,141	$11,715,098

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$96,202,126	1,229,106	-4.0%	Shares	Sole	2026-07-07
2026-03-31	$82,764,660	1,280,592	-1.7%	Shares	Sole	2026-04-14
2025-12-31	$87,636,714	1,302,180	-9.4%	Shares	Sole	2026-01-09
2025-09-30	$105,355,330	1,436,533	-21.7%	Shares	Sole	2025-10-10
2025-06-30	$95,478,080	1,835,411	-13.9%	Shares	Sole	2025-07-16
2025-03-31	$136,088,033	2,132,707	+8.8%	Shares	Sole	2025-04-11
2024-12-31	$93,694,978	1,959,736	-19.5%	Shares	Sole	2025-01-30
2024-09-30	$139,298,061	2,433,579	+446.5%	Shares	Sole	2024-10-28
2024-06-30	$23,318,054	445,341	+9.2%	Shares	Sole	2024-08-02
2024-03-31	$16,592,029	407,867	+16.2%	Shares	Sole	2024-04-11
2023-12-31	$12,975,768	351,076	+15.6%	Shares	Sole	2024-03-04
2023-09-30	$11,601,989	303,717	+5.1%	Shares	Sole	2023-11-01
2023-06-30	$10,427,981	289,104	—	Shares	Sole	2023-07-27
No filing history on record for this holder in this stock.